Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
NCT ID: NCT01981109
Last Updated: 2019-08-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
225 participants
OBSERVATIONAL
2012-01-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer
NCT03111914
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
NCT02042053
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT02856100
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
NCT03085043
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
NCT04928820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men ≥ 18 years of age.
* Histologically documented prostatic adenocarcinoma.
* History of Castration-Resistant Prostate Cancer.
Exclusion Criteria
* Undergone imaging study for metastatic prostate cancer ≤ 3 months.
* ECOG performance status ≥ 3.
* Known malignant pleural effusions or ascites.
* Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dendreon
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Brown, MD
Role: STUDY_DIRECTOR
Dendreon Pharmaceuticals, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Urological Associate of Southern Arizona
Tucson, Arizona, United States
Sequoia Urology Center
Atherton, California, United States
Prostate Oncology Specialist, Inc.
Marina del Rey, California, United States
Sutter Medical Group
Sacramento, California, United States
Genesis Research
San Diego, California, United States
Urology Associates of San Luis Obispo
Templeton, California, United States
The Urology Center of Colorado
Denver, Colorado, United States
Advanced Urology, P.C
Parker, Colorado, United States
Howard University Hospital
Washington D.C., District of Columbia, United States
Urology Center of South Florida
Miami, Florida, United States
Idaho Urologic Institute
Meridian, Idaho, United States
Comprehensive Urologic Care, SC
Lake Barrington, Illinois, United States
Uro Partners/ RMD Clinical Research
Melrose Park, Illinois, United States
Associated Urological Specialists, LLC
Palos Heights, Illinois, United States
1st Urology, PSC
Jeffersonville, Indiana, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
Kansas City Urology Care, PA
Overland Park, Kansas, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Jewish Hospital
Louisville, Kentucky, United States
Tulane University
New Orleans, Louisiana, United States
Highland Clinic
Shreveport, Louisiana, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Mid Atlantic Urology Associates
Greenbelt, Maryland, United States
Chesapeake Urology Research Associates
Towson, Maryland, United States
Michigan Institute of Urology
Troy, Michigan, United States
Metro Urology
Plymouth, Minnesota, United States
Metro Urology
Woodbury, Minnesota, United States
Saint Louis VAMS
St Louis, Missouri, United States
Southeast Nebraska Cancer Center
Lincoln, Nebraska, United States
Urology Center Research Institute
Englewood, New Jersey, United States
Delaware Valley Urology, LLC
Mount Laurel, New Jersey, United States
National Translational Research Group
East Setauket, New York, United States
Integrated Medical Professionals, PLLC
North Hills, New York, United States
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, United States
Associated Medical Professionals of NY, PLLC
Syracuse, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Durham Veterans Affairs Medical Center
Durham, North Carolina, United States
Carolina Urology Partners
Gastonia, North Carolina, United States
Central Ohio Urology Group
Gahanna, Ohio, United States
Clinical Research Solutions
Middleburg Heights, Ohio, United States
Stepherson Cancer Center
Oklahoma City, Oklahoma, United States
Portland Veterans Administration Medical Center
Portland, Oregon, United States
Oregon Urology Institute
Springfield, Oregon, United States
Urologic Consultants of SE PA
Bala-Cynwyd, Pennsylvania, United States
Urology Health Specialists, LLC
Bryn Mawr, Pennsylvania, United States
Lancaster Urology
Lancaster, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
The Conrad Pearson Clinic
Germantown, Tennessee, United States
Tennessee Urology Asociates
Knoxville, Tennessee, United States
Urology Associates, P.C.
Nashville, Tennessee, United States
Urology Clinics of North Texas
Dallas, Texas, United States
Houston Metro Urology
Houston, Texas, United States
UT Memorial Hermann Cancer Center
Houston, Texas, United States
Oncology San Antonio Research LLC
San Antonio, Texas, United States
Virginia Urology
Richmond, Virginia, United States
Urology of Virginia, PLLC
Virginia Beach, Virginia, United States
Medical Oncology Associates
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P12-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.